{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:13:40Z","timestamp":1754108020583,"version":"3.41.2"},"reference-count":46,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00867","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T07:22:25Z","timestamp":1511248945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases"],"prefix":"10.3389","volume":"8","author":[{"given":"Nicola","family":"Imperatore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rispo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Caporaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Morisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2013.07.014","article-title":"Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease","volume":"11","author":"Allen","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","article-title":"Biosimilars in inflammatory bowel disease: facts and fears of extrapolation","volume":"14","author":"Ben-Horin","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00054725-200111000-00002","article-title":"Hepatitis B and C virus infection in Crohn's disease","volume":"7","author":"Biancone","year":"2001","journal-title":"Inflamm. Bowel Dis."},{"key":"B4","first-page":"102","article-title":"Toxicity and risks from drug-to-drug interactions of new antivirals for chronic hepatitis C","volume":"21","author":"Binda","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"Risk of drug-induced liver injury from tumor necrosis factor antagonists","volume":"13","author":"Bj\u00f6rnsson","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.3748\/wjg.v22.i28.6444","article-title":"Management of psoriasis patients with hepatitis B or hepatitis C virus infection","volume":"22","author":"Bonifati","year":"2016","journal-title":"World J. Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1517\/14712598.2015.1011616","article-title":"Current evidence in the field of the management with TNF-\u03b1 inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection","volume":"15","author":"Caso","year":"2015","journal-title":"Expert Opin. Biol. Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/ibd.21147","article-title":"Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France","volume":"16","author":"Chevaux","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1097\/MIB.0000000000000126","article-title":"Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease","volume":"20","author":"Coban","year":"2014","journal-title":"Inflamm. Bowel Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1080\/17474124.2016.1246181","article-title":"Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection","volume":"10","author":"Degasperi","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","article-title":"Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C","volume":"140","author":"Dill","year":"2011","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on Treatment of Hepatitis C 2016","volume":"66","year":"2017","journal-title":"J. Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1600-0676.1996.tb00768.x","article-title":"Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C","volume":"16","author":"Fukuda","year":"1996","journal-title":"Liver"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct Acting anti-hepatitis C virus drugs: clinical pharmacology and future direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Transl. Int. Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2036.2010.04570.x","article-title":"Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease","volume":"33","author":"Gisbert","year":"2011","journal-title":"Aliment. Pharmacol. Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14014","article-title":"Potential drug-drug interactions of Ombitasvir, Paritaprevir\/Ritonavir \u00b1 Dasabuvir \u00b1 Ribavirin in clinical practice","author":"Gonz\u00e1lez-Colominas","year":"2017","journal-title":"J. Gastroenterol. Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/09546634.2013.825041","article-title":"An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis","volume":"25","author":"Gupta","year":"2014","journal-title":"J. Dermatolog. Treat"},{"key":"B18","doi-asserted-by":"publisher","first-page":"ofv091","DOI":"10.1093\/ofid\/ofv091","article-title":"Durable sustained virologic response after oral directly acting antiviral therapy despite immunosuppressive treatment","volume":"2","author":"Hahn","year":"2015","journal-title":"Open Forum Infect. Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"CD012143","DOI":"10.1002\/14651858.CD012143.pub3","article-title":"Direct-acting antivirals for chronic hepatitis C","volume":"9","author":"Jakobsen","year":"2017","journal-title":"Cochrane Database Syst. Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/apt.12601","article-title":"Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection","volume":"39","author":"Koff","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0172159","DOI":"10.1371\/journal.pone.0172159","article-title":"Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study","volume":"12","author":"Kondili","year":"2017","journal-title":"PLoS ONE"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3748\/wjg.v23.i9.1618","article-title":"Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions","volume":"23","author":"Langness","year":"2017","journal-title":"World J. Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti- adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobat\u00f3n","year":"2014","journal-title":"Aliment. Pharmacol. Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.crohns.2014.06.009","article-title":"Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3)","volume":"8","author":"Loras","year":"2014","journal-title":"J. Crohns. Colitis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ajg.2008.4","article-title":"Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study","volume":"104","author":"Loras","year":"2009","journal-title":"Am. J. Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1586\/17512433.2016.1129272","article-title":"New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir","volume":"9","author":"McConachie","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2893.2012.01643.x","article-title":"Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection","volume":"20","author":"Morisco","year":"2013","journal-title":"J. Viral Hepat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12876-016-0480-x","article-title":"Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report","volume":"16","author":"Ohta","year":"2016","journal-title":"BMC Gastroenterol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/ibd.21468","article-title":"Renal manifestations and complications of inflammatory bowel disease","volume":"17","author":"Oikonomou","year":"2011","journal-title":"Inflamm. Bowel Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.crohns.2012.03.001","article-title":"Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-\u03b1 agents","volume":"7","author":"Papa","year":"2013","journal-title":"J. Crohns. Colitis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma","author":"Persico","year":"2017","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann. Rheum. Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","article-title":"Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort","volume":"13","author":"Piga","year":"2014","journal-title":"Autoimmun. Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7867","DOI":"10.3748\/wjg.v19.i44.7867","article-title":"Tumor necrosis factor-\u03b1 inhibitors and chronic hepatitis C: a comprehensive literature review","volume":"19","author":"Pompili","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J. Crohns. Colitis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jhep.2017.02.010","article-title":"Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection","volume":"66","author":"Ramos-Casals","year":"2017","journal-title":"J. Hepatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and safety of sofosbuvir plus daclatasvir for the treatment of HCV-associated cryoglobulinemic vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/apt.13363","article-title":"Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease","volume":"42","author":"Safroneeva","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.3748\/wjg.v20.i13.3516","article-title":"Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease","volume":"20","author":"Sansone","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1365-2036.2008.03779.x","article-title":"Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C","volume":"28","author":"Scherzer","year":"2008","journal-title":"Aliment. Pharmacol. Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/MEG.0000000000000882","article-title":"Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration","volume":"29","author":"Tabernilla","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/14712598.2012.646986","article-title":"Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management","volume":"12","author":"Vigan\u00f2","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"B45","article-title":"No clinically meaningful pharmacokinetic interaction between HCV inhibitors grazoprevir\/elbasvir with tacrolimus, mycophenolate mofetil, and prednisolone, but cyclosporine increases grazoprevir\/elbasvir exposures in healthy subjects","volume-title":"66th Annual Meeting of the American Association for the Study of Liver Diseases","author":"Yeh","year":"2015"},{"key":"B46","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.autrev.2017.03.004","article-title":"International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement","volume":"16","author":"Zignego","year":"2017","journal-title":"Autoimmun. Rev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T07:22:25Z","timestamp":1511248945000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":46,"alternative-id":["10.3389\/fphar.2017.00867"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00867","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2017,11,21]]},"article-number":"867"}}